SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ — Gen-Probe
Incorporated (Nasdaq:
GPRO) announced today that the Company will present at the
Oppenheimer 21st Annual Healthcare Conference in New York on
November 2, 2010 at 11:25 a.m. Eastern time, and at the Lazard
Capital Markets 7th Annual Healthcare Conference in New York on
November 17, 2010 at 10 a.m. Eastern time. The presentations
are scheduled to be webcast live and may be accessed through a link
on the investors section of Gen-Probe’s website at www.gen-probe.com. The
webcasts will be available for 30 days following the events.
About Gen-ProbeGen-Probe Incorporated is a global leader in
the development, manufacture and marketing of rapid, accurate and
cost-effective molecular diagnostic products and services that are
used primarily to diagnose human diseases, screen donated human
blood, and ensure transplant compatibility. Gen-Probe has
approximately 27 years of expertise in nucleic acid testing (NAT),
and received the 2004 National Medal of Technology, America’s
highest honor for technological innovation, for developing NAT
assays for blood screening. Gen-Probe is headquartered in San
Diego and employs approximately 1,300 people. For more information,
go to www.gen-probe.com.
Caution Regarding Forward-Looking StatementsAny statements in
this press release about our expectations, beliefs, plans,
objectives, assumptions or future events or performance are not
historical facts and are forward-looking statements.
Forward-looking statements are not guarantees of performance.
They involve known and unknown risks, uncertainties and assumptions
that may cause actual results to differ materially from those
expressed or implied. For information about risks and
uncertainties we face and a discussion of our finan
‘/>”/>
SOURCE
